Intervention

Genvoya

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions12

Lead sponsors shown4

Clinical trials

5 shown

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis RegimensNCT03976752 · 2019-03-13

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution TherapyNCT03549312 · 2018-02-01

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure ProphylaxisNCT02998320 · 2017-03-10

Body Compartment PK for New HIV Pre-exposure Prophylaxis ModalitiesNCT02985996 · 2017-02-06

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected IndividualsNCT02251236 · 2016-01-01

Common conditions

HIV/AIDS2 Bone Diseases, Metabolic1 Buprenorphine Dependence1 Co-infection1 HCV Coinfection1 Hepatitis C, Chronic1 HIV1 HIV Infections1 HIV Risk1 HIV-1-infection1 Methadone Dependence1 Opioid Dependence1

Leading sponsors

Emory University2 Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux1 Saskatchewan Health Authority - Regina Area1 University of California, San Diego1

Trial status mix

COMPLETED4

UNKNOWN1

Phase mix

PHASE12

NA1

PHASE31

PHASE41

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.